These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 26769887

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
    Krakower D, Mayer KH.
    Ann Intern Med; 2012 Oct 02; 157(7):490-7. PubMed ID: 22821365
    [Abstract] [Full Text] [Related]

  • 3. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG, PrEP Brasil Study Team.
    Lancet HIV; 2018 Mar 02; 5(3):e136-e145. PubMed ID: 29467098
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.
    Leech AA, Burgess JF, Sullivan M, Kuohung W, Horný M, Drainoni ML, Christiansen CL, Linas BP.
    AIDS; 2018 Nov 28; 32(18):2787-2798. PubMed ID: 30234602
    [Abstract] [Full Text] [Related]

  • 5. Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications.
    Baker J, OʼHara KM.
    JAAPA; 2014 Dec 28; 27(12):10-7. PubMed ID: 25390822
    [Abstract] [Full Text] [Related]

  • 6. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM, iPrEx investigators.
    Lancet HIV; 2015 Dec 28; 2(12):e512-9. PubMed ID: 26614965
    [Abstract] [Full Text] [Related]

  • 7. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM, Mellors JW.
    Curr Opin HIV AIDS; 2016 Jan 28; 11(1):49-55. PubMed ID: 26633640
    [Abstract] [Full Text] [Related]

  • 8. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E, Cohan D.
    AIDS; 2013 Jan 02; 27(1):F1-5. PubMed ID: 22914582
    [Abstract] [Full Text] [Related]

  • 9. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J, Dufrene SL, Okulicz JF.
    Ann Pharmacother; 2014 Apr 02; 48(4):507-18. PubMed ID: 24473492
    [Abstract] [Full Text] [Related]

  • 10. Update on HIV prevention and preexposure prophylaxis.
    Baker J, Rolls J.
    JAAPA; 2020 Jun 02; 33(6):12-17. PubMed ID: 32384293
    [Abstract] [Full Text] [Related]

  • 11. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
    Haberer JE.
    Curr Opin HIV AIDS; 2016 Jan 02; 11(1):10-7. PubMed ID: 26633638
    [Abstract] [Full Text] [Related]

  • 12. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS, Mayer KH.
    Drugs; 2015 Feb 02; 75(3):243-51. PubMed ID: 25673022
    [Abstract] [Full Text] [Related]

  • 13. Nondaily preexposure prophylaxis for HIV prevention.
    Anderson PL, García-Lerma JG, Heneine W.
    Curr Opin HIV AIDS; 2016 Jan 02; 11(1):94-101. PubMed ID: 26633641
    [Abstract] [Full Text] [Related]

  • 14. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R.
    Drugs; 2019 Aug 02; 79(12):1263-1276. PubMed ID: 31309457
    [Abstract] [Full Text] [Related]

  • 15. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM, Mayer KH.
    AIDS Patient Care STDS; 2011 Feb 02; 25(2):63-71. PubMed ID: 21284497
    [Abstract] [Full Text] [Related]

  • 16. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    McAllister JW, Towns JM, Mcnulty A, Pierce AB, Foster R, Richardson R, Carr A.
    AIDS; 2017 Jun 01; 31(9):1291-1295. PubMed ID: 28301425
    [Abstract] [Full Text] [Related]

  • 17. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
    US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    JAMA; 2019 Jun 11; 321(22):2203-2213. PubMed ID: 31184747
    [Abstract] [Full Text] [Related]

  • 18. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.
    Mugo PM, Sanders EJ, Mutua G, van der Elst E, Anzala O, Barin B, Bangsberg DR, Priddy FH, Haberer JE.
    AIDS Behav; 2015 May 11; 19(5):794-801. PubMed ID: 25432877
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V, Miners A, Dunn D, McCormack S, Ong KJ, Gill ON, Nardone A, Desai M, Field N, Hart G, Delpech V, Cairns G, Rodger A, Phillips AN.
    Lancet Infect Dis; 2018 Jan 11; 18(1):85-94. PubMed ID: 29054789
    [Abstract] [Full Text] [Related]

  • 20. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, Walensky RP.
    Clin Infect Dis; 2009 Mar 15; 48(6):806-15. PubMed ID: 19193111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.